Citations

Clear

7552 citation(s) found for "Ku, Matthew".

eQTL in diseased colon tissue identifies novel target genes associated with IBD
Furey, Terrence S. , Nishiyama, Nina C. , Silverstein, Sophie , Darlington, Kimberly , Ng, Meaghan Kennedy, Clough, Katelyn , Bauer, Mikaela J., Beasley, Caroline, Bharadwaj, Akshatha, Ganesan, Rajee , Lau, Gwen, Lian, Grace , Rahbar, Reza, Sadiq, Timothy S., Schaner, Matthew R. , Stem, Jonathan, Friton, Jessica, Faubion, William A. , Sheikh, Shehzad Z. , Ng, Meaghan M. Kennedy , Kapadia, Muneera Rehana

Mayo Clinic

No container title available | October 3, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5147457/v1 Get It

Abstract Genome-wide association studies (GWAS) have identified over 300 loci associated with the inflammatory bowel diseases (IBD), but putative causal genes for most are unknown. We conducted the largest disease-focused expression quantitative trait loci (eQTL) analysis using colon tissue from 252 IBD patients to determine genetic effects on gene expression and potential contribution to IBD. Combined with two non-IBD colon eQTL studies, we identified 194 potential target genes for 108 GWAS loci. eQTL in IBD tissue were enriched for IBD GWAS loci colocalizations, provided novel evidence for IBD-associated genes such as ABO and TNFRSF14, and identified additional target genes compared to non-IBD tissue eQTL. IBD-associated eQTL unique to diseased tissue had distinct regulatory and functional characteristics with increased effect sizes. Together, these highlight the importance of eQTL studies in diseased tissue for understanding functional consequences of genetic variants, and elucidating molecular mechanisms and regulation of key genes involved in IBD.
Six-year follow-up of a world record-breaking master marathon runner
Romberger, Nathan T. , Stock, Joseph M. , McMillan, Ronald , Overstreet, Matthew, Lepers, Romuald , Joyner, Michael J. , Farquhar, William B. , McMillan, Ronald K , Joyner, Michael J

Mayo Clinic

Journal of Applied Physiology | October 3, 2024 | Volume: 137 | Issue: 5 | Pages: 1354-1358

10.1152/japplphysiol.00474.2024 | PMID 39359184 Get It

We performed 6-yr follow-up testing on a world record-breaking master marathon runner. We determined that his performance declined since his record-breaking marathon in 2018 primarily due to a reduction in V̇o2max. His max heart rate (HR) changed minimally, but his peak O2 pulse decreased, suggesting that his maximal stroke volume and/or arteriovenous O2 difference decreased. These changes likely reflect primarily age-related effects in the absence of an overt pathological disease process.
Detection of Residual iPSCs Following Differentiation of iPSC-Derived Retinal Pigment Epithelial Cells
Hill, Matthew, Andrews‐Pfannkoch, Cynthia, Atherton, Evan, Knudsen, Travis, Trncic, Emma , Marmorstein, Alan D. , Marmorstein, Alan D

Mayo Clinic

Journal of Ocular Pharmacology and Therapeutics | October 3, 2024 | Volume: 40 | Issue: 10 | Pages: 680-687

10.1089/jop.2024.0130 | PMID 39358867 Get It

Purpose: The goal of this study was to develop a lot release assay for iPSC residuals following directed differentiation of iPSCs to retinal pigment epithelial (RPE) cells. Methods: RNA Sequencing (RNA Seq) of iPSCs and RPE derived from them was used to identify pluripotency markers downregulated in RPE cells. Quantitative real time PCR (qPCR) was then applied to assess iPSC residuals in iPSC-derived RPE. The limit of detection (LOD) of the assay was determined by performing spike-in assays with known quantities of iPSCs serially diluted into an RPE suspension. Results: ZSCAN10 and LIN28A were among 8 pluripotency markers identified by RNA Seq as downregulated in RPE. Based on copy number and expression of pseudogenes and lncRNAs ZSCAN10 and LIN28A were chosen for use in qPCR assays for residual iPSCs. Reverse transcription PCR indicated generally uniform expression of ZSCAN10 and LIN28A in 21 clones derived from 8 iPSC donors with no expression of either in RPE cells derived from 5 donor lines. Based on qPCR, ZSCAN10 , and LIN28A expression in iPSCs was generally uniform. The LOD for ZSCAN10 and LIN28A in qPCR assays was determined using spike in assays of RPE derived from 2 iPSC lines. Analysis of ΔΔC t found the limit of detection to be <0.01% of cells, equivalent to <1 iPSC/10,000 RPE cells in both iPSC lines. Conclusions: qPCR for ZSCAN10 and LIN28A detects <1 in 10,000 residual iPSCs in a population of iPSC-derived RPE providing an adequate LOD of iPSC residuals for lot release testing.
Hypomagnesemia in Large B cell Lymphoma patients receiving CAR T cell therapy correlates with immune dysregulation and decreased PFS: results from the ZUMA-1 trial and Mayo Clinic cohort
Bansal, Radhika , Gandhi, Sangeetha, Babadi, Elham , Martinez, Kodi, McCoy, Gabrielle, Shao, Zuoyi , Regan, Kevin M., Hathcock, Matthew , Wang, Panwen , Ruan, Gordon, Ansell, Stephen M., Johnston, Patrick B., Khurana, Arushi , Hampel, Paul J. , Moreno, Eider, Kharfan‐Dabaja, Mohamed A. , Kim, Jenny , Shen, Rhine R. , Mattie, Mike , Lin, Yi , Witzig, Thomas E., Gile, Jennifer , Mondello, Patrizia , Wang, Zixing , Li, Ying , Zhang, Henan , Wang, Junwen , Saleh, Abdullah S. Al , Ansell, Stephen M. , Bennani, N. Nora , Johnston, Patrick B. , Paludo, Jonas , Villasboas, José C. , Durani, Urshila , Wang, Yucai , Rosenthal, Allison , Muñoz, Javier , Castro, Januario E. , Murthy, Hemant S. , Kenderian, Saad S.

Mayo Clinic

No container title available | October 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4889200/v1 Get It

Abstract Background Hypomagnesemia has been correlated with inferior outcomes in patients with large B cell lymphoma (LBCL) undergoing stem cell transplants. As T-cell and myeloid cell dysfunction have been associated with low magnesium conditions, we investigated whether serum magnesium (Mg) levels could predict clinical outcomes in LBCL patients who received chimeric antigen receptor T-cell therapy. Methods Patients with LBCL who received axi-cel under the ZUMA-1 trial or as FDA approved therapy at Mayo Clinic were examined. Serum samples were obtained at specified time points and cytokine analysis was performed. Single cell RNA sequencing was performed on peripheral blood mononuclear cells. The Student T-test, Kruskal Wallis, or Fisher's Exact Tests were used to compare differences in demographics across Mg levels. Survival curves were plotted using the Kaplan-Meier methodology and compared using the Wilcoxon test. Results We found that hypomagnesemia before lymphodepletion chemotherapy predicted for inferior progression-free and overall survival in the pivotal study ZUMA-1 (NCT02348216). These results were validated in an independent cohort of LBCL patients receiving axicabtagene ciloleucel (axi-cel) at Mayo Clinic. Hypomagnesemia correlated with increased inflammatory serum markers and cytokine levels including ferritin, IL-6, IL1Ra, IL-8, and MIP1a. scRNAseq analysis unveiled altered immune interactions between monocytes and T cells with a concordant immune suppressive transcriptome. Conclusions Hypomagnesemia at the time of CAR-T infusion associates with an unfavorable inflammatory profile and decreased response and survival in LBCL patients receiving axi-cel. These findings suggest a potentially actionable prognostic factor for patients with large cell lymphoma undergoing CAR-T.
Transcriptomic changes during the replicative senescence of human articular chondrocytes
Atasoy‐Zeybek, Aysegul , Hawse, Gresin P. , Nagelli, Christopher V. , Padilla, Consuelo Lopez De , Evans, Christopher H. , Padilla, Consuelo M. López de , Abdel, Matthew P.

Mayo Clinic

No container title available | October 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4876006/v1 Get It

Abstract Objective Aging is a major risk factor for OA, but the specific mechanisms underlying this connection remain unclear. Although chondrocytes rarely divide in adult articular cartilage, they undergo replicative senescence in vitro which provides an opportunity to study changes related to aging under controlled laboratory conditions. Methods Cartilage was recovered from two knees with OA and one normal knee. Chondrocyte cultures were established and sub-cultured until their Hayflick limit. Bulk RNA sequencing on early- and late-passage human articular chondrocytes allowed identification of transcriptomic changes associated with cellular aging. Results One male (80 years old) and one female (72 years old) patient provided OA cartilage. The donor of normal chondrocytes was a 26-year old male. Early passage chondrocytes from the two OA samples already had the phenotype of senescing cells, unlike normal chondrocytes. Nevertheless, all three chondrocyte cultures underwent 30 population doublings before replicative exhaustion, by which point all cells displayed a senescent phenotype. During this process, the cells lost their ability to form cartilaginous pellets. Differentially expressed genes (DEGs) analysis confirmed distinct transcriptomic profiles between early- and late-passage chondrocytes, as well as between cells isolated from normal and OA cartilage. Various changes in expression of genes related to cartilage matrix synthesis, degradation, inflammation and the senescence-associated secretory phenotype (SASP) were noted. Conclusions Although only a small pilot study, its data suggest that a larger and deeper study of the molecular and metabolic events accompanying the senescence of chondrocytes could provide important insights into the pathobiology of OA.
Immune checkpoint dysregulation in COVID-19 pathogenesis and disease severity.
Villalba, Julian A. , Shih, Angela , Alba, George A. , Loyola-Rodríguez, Georgina, Alcántara, Ismael Ramírez, Ferreira, Luíz Carlos de Lima , Stigliano, Egidio, Hirschbühl, Klaus , Argueta, Allan , Ackermann, Maximillian , Werlein, Christopher , Uribe‐Uribe, Norma , Vázquez-Benítez, Greissy, Tzankov, Alexandar , Stalder, Anna K. , Francesqui, Joel , Osborn, Michael , Hanley, Brian , Johnston, Robert, Lacy, J. Matthew , Marshall, Desiree A. , Schwensen, Hanna Ferløv , Okudela, Koji , Flikweert, Antine, Iles, Linda , d’Amati, Giulia , Träger, Lene Hoffmann , Çınar, Hüseyin, Aguiar, Diego , Dolhnokoff, Marisa, Chilosi, Marco , Salmon, I, Colville‐Ebeling, Bonnie, Poissy, Julien , Haahr, Martha Kirstine , Reyes, Fabiola, Parry, Blair A. , Garlin, Michelle, Hilburn, Caroline F., ELLIOTT, G. A., Rosas, Iván O. , Sade-Feldman, Moshe , Hacohen, Nir , Baden, Lindsey R. , Li, Jonathan Z. , Schaller, Tina , Gigli, L, Macciò, Umberto , Yick, David C.Y., Bruni, Barbara, Pernazza, Angelina , Mauad, Thaís , Dubini, Alessandra, Hartmann, Arndt, Remmelink, Myriam , Aviles, Alexis J., Barth, Jamie L., Boyraz, Bariş , Araujo-Medina, Milagros, Mendez-Pena, Javier E., Chebib, Ivan , Hung, Yin P. , Rosales, Ivy A. , Smith, Rex-Neal, Hung, Yin P , Tzankov, Alexandar , Li, Yijia , Poli, Sergio , Kunitoki, Keiko , Mehta, Arnav , Santana, Monique Freire , Lacerda, Marcus , Dell’Aquila, Marco , Arena, Vincenzo , Calabrese, Fiorella , Pezzuto, Federica , Märkl, Bruno , Lozano, Maria, Jonigk, Danny David , Pomara, Cristoforo , Salerno, Monica , Salas, Clara , Martínez, Daniel, Parra-Medina, Rafael Santiago , Bradley, Benjamin T. , Chen, Sonja , Varga, Zsuzsanna , Steinestel, Konrad , Harper, Holly , Aiolfi, Alberto , Scendoni, Roberto , Fabro, Alexandre Todorovic , Doglioni, Claudio , Rossi, Giulio , Poletti, Venerino , Herrmann, Martin , Pugh, Matthew , Yan, Lei , Gentili, Matteo , Garlin, Michelle A., Lo, Ying‐Chun , Elliott, Grant, Martínez, Leonardo , Stone, James R. , Colvin, Robert B. , Goldberg, Marcia B. , Filbin, Michael R. , Mino-Kenudson, Mari A. , Kröncke, Thomas J. , Gigli, Laura Álvarez, Sessa, Francesco , Caltabiano, Rosario , Menter, Thomas , Sellarés, Jacobo , Storgaard, Merete , Hamilton‐Dutoit, Stephen , Dannheim, Katelyn , Witte, Hanno Maximilian , Bona, Davide , Leth, Peter Mygind , Banner, Jytte , Batah, Sabrina Setembre , Silva, Luiz Fernando Ferraz da , Duarte‐Neto, Amaro Nunes , Saldiva, Paulo Hilário Nascimento , Munoz, Luis Enrique , Jensen, T. , Brøchner, Christian Beltoft , Gibier, Jean‐Baptiste , Gilbert, Andrea , Madrigal, Emilio , Ly, Amy , Hariri, Lida P. , Caldwell, Nicholas J

Mayo Clinic

No container title available | October 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3508654/v1 Get It

Abstract Accumulating evidence suggests dysregulated immune checkpoint (IC) signaling can exacerbate COVID-19 severity, but the role of these molecules in the pathogenesis of fatal COVID-19-related diffuse alveolar damage (DAD) remains elusive. Understanding how IC proteins influence acute lung injury due to COVID-19 can provide insights into potential therapeutic strategies to modulate immune responses and improve patient outcomes. Here, in a single-center autopsy cohort, we determined the cellular localization of ICs in lung tissue from cases of fatal COVID-19, DAD-comparators, and non-fibrotic controls by using immunohistochemistry, and investigated their association with clinical outcomes. We expanded our findings by performing analyses of publicly available single-cell RNA sequencing datasets from patients with fatal COVID-19 and non-fibrotic controls. We demonstrated the presence of protein-protein interaction networks of ICs in the lung cellular niche by performing transcriptomic profiling of lung tissue-derived RNA counts from patients with fatal COVID-19. Further, we leveraged data from the largest international, multi-center COVID-19 autopsy cohort and validated that, among patients with fatal COVID-19, those with higher PD-L1/CD274 expression in lung endothelial cells had more rapid clinical deterioration. Lastly, in a cohort of individuals with early COVID-19, IC plasma protein levels were elevated in those with persistent SARS-CoV-2 RNAemia and adverse clinical outcomes. Collectively, our data provide unique pathological insights into the role of IC dysregulation and differential disease severity in COVID-19.
Endovascular Ablation of the Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction
Fudim, Marat , Mohan, Rajeev , Price, Matthew J. , Fail, Peter , Hummel, Scott L. , Zirakashvili, Teona, Shaburishvili, Tamaz, Nielsen, Christopher D., Chetcuti, Stanley, Sukul, Devraj , Gulati, Rajiv, Kim, Luke , Benzuly, Keith, Mitter, Sumeet S. , Klein, Liviu , Uriel, Nir , Augostini, Ralph , Blair, John E. , Rocha‐Singh, Krishna J. , Patel, Manesh R. , Somo, Sami I., Hummel, Scott L , Borlaug, Barry A. , Goyal, Parag , Patel, Ravi B. , Reddy, Vivek Y. , Gulati, Rajiv , Burkhoff, Daniel , Litwin, Sheldon E. , Shah, Sanjiv J

Mayo Clinic

JAMA Cardiology | October 2, 2024 | Volume: 9 | Issue: 12 | Pages: 1143

10.1001/jamacardio.2024.2612 | PMID 39356530 Get It

ImportanceGreater splanchnic nerve ablation may improve hemodynamics in patients with heart failure and preserved ejection fraction (HFpEF).ObjectiveTo explore the feasibility and safety of endovascular right-sided splanchnic nerve ablation for volume management (SAVM).Design, Setting, and ParticipantsThis was a phase 2, double-blind, 1:1, sham-controlled, multicenter, randomized clinical trial conducted at 14 centers in the US and 1 center in the Republic of Georgia. Patients with HFpEF, left ventricular ejection fraction of 40% or greater, and invasively measured peak exercise pulmonary capillary wedge pressure (PCWP) of 25 mm Hg or greater were included. Study data were analyzed from May 2023 to June 2024.InterventionSAVM vs sham control procedure.Main Outcomes and MeasuresThe primary efficacy end point was a reduction in legs-up and exercise PCWP at 1 month. The primary safety end point was serious device- or procedure-related adverse events at 1 month. Secondary efficacy end points included HF hospitalizations, changes in exercise function and health status through 12 months, and baseline to 1-month change in resting, legs-up, and 20-W exercise PCWP.ResultsA total of 90 patients (median [range] age, 71 [47-90] years; 58 female [64.4%]) were randomized at 15 centers (44 SAVM vs 46 sham). There were no differences in adverse events between groups. The primary efficacy end point did not differ between SAVM or sham (mean between-group difference in PCWP, −0.03 mm Hg; 95% CI, −2.5 to 2.5 mm Hg; P = .95). There were also no differences in the secondary efficacy end points. There was no difference in the primary safety end point between the treatment (6.8% [3 of 44]) and sham (2.2% [1 of 46]) groups (difference, 4.6%; 95% CI, −6.1% to 15.4%; P = .36). There was no difference in the incidence of orthostatic hypotension between the treatment (11.4% [5 of 44]) and sham (6.5% [3 of 46]) groups (difference, 4.9%; 95% CI, −9.2% to 18.8%; P = .48).Conclusions and RelevanceResults show that SAVM was safe and technically feasible, but it did not reduce exercise PCWP at 1 month or improve clinical outcomes at 12 months in a broad population of patients with HFpEF.Trial RegistrationClinicalTrials.gov Identifier: NCT04592445
A-301 Evaluation of Second-Generation Visby Medical Sexual Health Point-of-Care Test: Clinical Concordance, Analytical Error Rates, and Result Turnaround Time
Kelley, Barbara R, Wockenfus, Amy M., Binnicker, Matthew J. , Karon, Barry L., Kelley, B, Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | October 2, 2024 | Volume: 70 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvae106.298 Get It

Abstract Background Rapid testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis may be useful for antibiotic stewardship initiatives. Our institution recently implemented the second-generation Visby Medical Sexual Health Test (Visby Gen2) for rapid diagnosis of STIs in our emergency department. Here we (1) compared result concordance of the (Visby Gen2) to the first-generation Visby Medical Sexual Health Click Test (Visby Gen1), (2) compared assay failure rates of the Visby Gen1 to Gen2 tests, and (3) compared result turnaround time (TAT) for clinically ordered rapid STI tests to central laboratory STI results. Methods Accuracy was assessed using residual clinical samples in Aptima buffer submitted for routine molecular STI testing (C. trachomatis, N. gonorrhoeae, and T. vaginalis) in the central laboratory on the Panther platform (Hologic). Aptima samples were diluted 1:33 in Visby collection buffer prior to testing on the Visby cartridge. Clinically reported results were used as reference results. Diluted samples with discordant results were re-tested on the reference method and the result from the dilution was used in calculations. Assay failure rates were calculated as the number of failed assays compared to the total assays performed. TAT for rapid and central lab testing was calculated as time of sample received in laboratory to time verified in laboratory information system. Results For Visby Gen1 we observed negative concordance of 100% (41/41) for C. trachomatis, 97.5% (39/40) for N. gonorrhoeae, and 97.1% (34/35) for T. vaginalis. Positive concordance was 91.7% (11/12) for C. trachomatis, 100% (11/11) for N. gonorrhoeae, and 100% (17/17) for T. vaginalis. For Visby Gen1 we observed a 10.5% (12/114) cartridge failure rate. For Visby Gen2, we observed negative concordance of 100% (59/59) for C. trachomatis, 100% (63/63) for N. gonorrhoeae, and 100% (55/55) for T. vaginalis while positive concordance was 100% (10/10) for C. trachomatis, 100% (6/6) for N. gonorrhoeae, and 90.9% (10/11) for T. vaginalis. The Visby Gen2 assay displayed a 4.9% (4/81) cartridge failure rate. Six weeks after implementing the Visby Gen2 assay in our ED, rapid STI panel TAT was 0.48 hours on average (n=20). In the central laboratory the average TAT was 22.31 hours (n=7892). Conclusions Assay concordance to reference method was similar for Visby Gen1 and Gen2 assays. The cartridge failure rate improved by 46.7% with the Gen2 assay which should decrease the need to repeat testing due to assay failure. Result TAT decreased by 97.8% when comparing rapid Visby results to central laboratory. Therefore, Visby STI testing using the Gen2 assay can provide accuracy and rapid results likely to facilitate more rapid patient management.
B-355 Assessment of Calcitonin Cutoff Values for Post-Thyroidectomy Surveillance in Patients with Medullary Thyroid Carcinoma: Findings from a Single-Center Investigation
Li, Shujun , Lee, J K, Azaryan, Irina , Nabhan, Fadi , Jones, Jeffrey A. , Patton, A, Scheidegger, M, Sipos, Jennifer A. , Algeciras‐Schimnich, Alicia , Ringel, Matthew D.

Mayo Clinic

Clinical Chemistry | October 2, 2024 | Volume: 70 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvae106.712 Get It

Abstract Background Patients with sporadic or hereditary Medullary Thyroid Carcinoma (MTC) often undergo total thyroidectomy and lymph node dissection, with postoperative surveillance relying on serum calcitonin levels and ultrasound examinations. According to American Thyroid Association (ATA) guidelines, detectable levels of serum calcitonin and Carcinoembryonic Antigen (CEA) post-thyroidectomy suggest potential disease persistence or recurrence, necessitating frequent monitoring for early detection. This study sought to reassess the role of postoperative calcitonin levels in identifying possible tumor recurrence. Methods A retrospective analysis was conducted using Siemens Atellica to test calcitonin levels in 562 samples collected between 09/27/2022 and 08/11/2023, at least 3 months post-total thyroidectomy. Imaging studies performed within 6 months of the calcitonin assessment were also reviewed. Sample pools with calcitonin concentrations near 3.00 and 5.00 pg/mL were utilized to determine the limit of quantification (LoQ). CEA results were included for comparison. Additionally, 16 serum samples were analyzed using the Roche Cobas system at a reference laboratory. Results Precision analysis around 3.00 and 5.00 pg/mL revealed coefficients of variation (CVs) of 16.49% and 8.87%, respectively. Comparison of calcitonin levels between Siemens Atellica and Roche Cobas systems demonstrated consistent levels &lt; 5.00 pg/mL in 15 out of 16 samples, indicating alignment and reliability between the platforms. A calcitonin cutoff of 1.89 pg/mL yielded 43% sensitivity and 67% specificity, while a cutoff of 5.00 pg/mL resulted in 0% sensitivity and 100% specificity. Conclusions Our findings suggest that a 5 pg/mL calcitonin cutoff on the Siemens Atellica platform may be suitable for identifying tumor persistence or recurrence in post-thyroidectomy patients within our institution. However, individual laboratories should establish their LoQ criteria when interpreting calcitonin levels for postoperative monitoring of tumor recurrence.
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Buras, Matthew R., Carter, Rickey E. , Joyner, Michael J. , Bloch, Evan M. , Henderson, Jeffrey P. , Senefeld, Jonathon W. , Wright, R. Scott , Carter, Rickey E , Joyner, Michael J , Henderson, Jeffrey P , Shoham, Shmuel , Sullivan, David J , Casadevall, Arturo , Senefeld, Jonathon W , Dragotakes, Quigly , Johnson, Patrick W. , Gebo, Kelly A , Hanley, Daniel F. , Pirofski, Liise‐anne , Shoham, Shmuel , Tobian, Aaron A.R. , Wiggins, Chad C. , Paneth, Nigel , Sullivan, David , Casadevall, Arturo

Mayo Clinic

Proceedings of the National Academy of Sciences | October 1, 2024 | Volume: 121 | Issue: 41 | Pages: No page available

10.1073/pnas.2414957121 | PMID 39352932 Get It

In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we estimated the number of actual inpatient lives saved by CCP treatment in the United States of America based on CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15 to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, we estimated that CCP saved between 16,476 and 66,296 lives. The CCP ideal use might have saved as many as 234,869 lives and prevented 1,136,133 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma use in future infectious disease emergencies.